ARTELO BIOSCIENCES, INC.

Artelo Biosciences announced encouraging metabolite identification and profiling data for its lead FABP inhibitor candidate, ART26.12, from a recently completed Single Ascending Dose (SAD) clinical study. The data, presented at a conference, showed a low-risk metabolite profile with only three metabolites detected, representing approximately 7% of total drug-related exposure. These findings are expected to streamline future development, reduce program risk, and strengthen confidence in ART26.12's advancement for pain treatment.

Artelo Biosciences, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on July 17, 2026. Stockholders will vote on the election of three Class III director nominees and a proposal to amend the Articles of Incorporation to increase the authorized shares of common stock from 166,666,667 to 500,000,000. The Board of Directors recommends voting "FOR" all proposals.

Artelo Biosciences, Inc. has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to sell up to $6,530,000 of its common stock. This program allows the company to raise capital from time to time, with the sales agent receiving a 3.0% commission on gross sales. Separately, Craft Capital Management LLC has filed a FINRA arbitration claim against Artelo Biosciences, seeking $880,000 in success fees and $880,000 in common stock warrants, alleging a breach of contract related to a prior $11 million private placement.

Artelo Biosciences, Inc. announced the termination of its At-The-Market Offering Agreement with R.F. Lafferty & Co., Inc., effective May 18, 2026. The agreement, established on July 18, 2025, allowed the company to offer and sell up to $6.5 million in common stock. Prior to termination, Artelo Biosciences had sold 50,858 shares, generating gross proceeds of $451,526.95.

Artelo Biosciences reported a net loss of $2.958 million for Q1 2026, an increase from $2.372 million in Q1 2025. Despite the increased loss, the company significantly improved its financial position, with cash and cash equivalents rising to $10.273 million from $0.600 million at year-end 2025, and stockholders' equity turning positive to $6.672 million from a deficit of $1.272 million. This improvement was primarily driven by $10.033 million in net proceeds from a private placement offering in March 2026, which also included the issuance of warrants and convertible notes. The company acknowledged substantial doubt about its ability to continue as a going concern, but the recent financing provides immediate capital.

Artelo Biosciences, Inc. announced a strategic partnership with BioAI company ScienceMachine to accelerate the development of its fatty acid-binding protein 5 (FABP5) inhibitor platform. ScienceMachine's AI technology will analyze Artelo's FABP datasets to identify novel biological insights, mechanisms, and therapeutic opportunities for FABP5 inhibitors, particularly ART26.12. The collaboration, which began in 2025, has already identified potential proteins for target engagement and revealed latent biological networks, with preliminary psoriasis model results expected later this year. This partnership is anticipated to enhance R&D precision, accelerate biomarker identification, and prioritize follow-on compounds, shortening the path to value creation.

Artelo Biosciences received notification from Nasdaq confirming it has regained compliance with the minimum stockholders' equity requirement ($2.5 million) and the annual meeting requirement. The company will be subject to a mandatory panel monitor through April 6, 2027, and faces potential delisting if it falls out of compliance with the equity rule again during that period.